GLUCOVANCE®
(Glyburide and Metformin HCl) Tablets

2.5 mg/500 mg
5 mg/500 mg

DESCRIPTION

GLUCOVANCE® (Glyburide and Metformin HCl) Tablets contain 2 oral antihyperglycemic drugs used in the management of type 2 diabetes, glyburide and metformin hydrochloride.

Glyburide is an oral antihyperglycemic drug of the sulfonylurea class. The chemical name for glyburide is 1-[[p-[2-(5-chloro-o-anisamido)ethyl]phenyl]sulfonyl]-3-cyclo-hexylurea. Glyburide is a white to off-white crystalline compound with a molecular formula of C_{23}H_{28}ClN_{3}O_{5}S and a molecular weight of 494.01. The glyburide used in GLUCOVANCE has a particle size distribution of 25% undersize value not more than 6 µm, 50% undersize value not more than 7 to 10 µm, and 75% undersize value not more than 21 µm. The structural formula is represented below.

![Glyburide Structural Formula](image)

Metformin hydrochloride is an oral antihyperglycemic drug used in the management of type 2 diabetes. Metformin hydrochloride (N,N-dimethylimidodicarbonimidic diamide monohydrochloride) is not chemically or pharmacologically related to sulfonylureas, thiazolidinediones, or α-glucosidase inhibitors. It is a white to off-white crystalline compound with a molecular formula of C_{4}H_{12}ClN_{5} (monohydrochloride) and a molecular weight of 165.63. Metformin hydrochloride is freely soluble in water and is practically insoluble in acetone, ether, and chloroform. The pKₐ of metformin is 12.4. The pH of a 1% aqueous solution of metformin hydrochloride is 6.68. The structural formula is as shown:
GLUCOVANCE is available for oral administration in tablets containing 2.5 mg glyburide with 500 mg metformin hydrochloride, and 5 mg glyburide with 500 mg metformin hydrochloride. In addition, each tablet contains the following inactive ingredients: microcrystalline cellulose, povidone, croscarmellose sodium, and magnesium stearate. The tablets are film coated, which provides color differentiation.

**CLINICAL PHARMACOLOGY**

**Mechanism of Action**

GLUCOVANCE combines glyburide and metformin hydrochloride, 2 antihyperglycemic agents with complementary mechanisms of action, to improve glycemic control in patients with type 2 diabetes.

Glyburide appears to lower blood glucose acutely by stimulating the release of insulin from the pancreas, an effect dependent upon functioning beta cells in the pancreatic islets. The mechanism by which glyburide lowers blood glucose during long-term administration has not been clearly established. With chronic administration in patients with type 2 diabetes, the blood glucose-lowering effect persists despite a gradual decline in the insulin secretory response to the drug. Extrapancreatic effects may be involved in the mechanism of action of oral sulfonlurea hypoglycemic drugs.

Metformin hydrochloride is an antihyperglycemic agent that improves glucose tolerance in patients with type 2 diabetes, lowering both basal and postprandial plasma glucose. Metformin hydrochloride decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization.
Pharmacokinetics

Absorption and Bioavailability

**GLUCOVANCE**

In bioavailability studies of GLUCOVANCE 2.5 mg/500 mg and 5 mg/500 mg, the mean area under the plasma concentration versus time curve (AUC) for the glyburide component was 18% and 7%, respectively, greater than that of the MICRONASE® brand of glyburide coadministered with metformin. The glyburide component of GLUCOVANCE, therefore, is not bioequivalent to MICRONASE®. The metformin component of GLUCOVANCE is bioequivalent to metformin coadministered with glyburide.

Following administration of a single GLUCOVANCE 5 mg/500 mg tablet with either a 20% glucose solution or a 20% glucose solution with food, there was no effect of food on the C_max and a relatively small effect of food on the AUC of the glyburide component. The T_max for the glyburide component was shortened from 7.5 hours to 2.75 hours with food compared to the same tablet strength administered fasting with a 20% glucose solution. The clinical significance of an earlier T_max for glyburide after food is not known. The effect of food on the pharmacokinetics of the metformin component was indeterminate.

**Glyburide**

Single-dose studies with MICRONASE® tablets in normal subjects demonstrate significant absorption of glyburide within 1 hour, peak drug levels at about 4 hours, and low but detectable levels at 24 hours. Mean serum levels of glyburide, as reflected by areas under the serum concentration-time curve, increase in proportion to corresponding increases in dose. Bioequivalence has not been established between GLUCOVANCE and single-ingredient glyburide products.

**Metformin Hydrochloride**

The absolute bioavailability of a 500 mg metformin hydrochloride tablet given under fasting conditions is approximately 50% to 60%. Studies using single oral doses of metformin tablets of 500 mg and 1500 mg, and 850 mg to 2550 mg, indicate that there is a lack of dose proportionality with increasing doses, which is due to decreased absorption rather than an alteration in elimination. Food decreases the extent of and slightly delays the absorption of metformin, as shown by approximately a 40% lower peak concentration and a 25% lower AUC in plasma and a 35-minute prolongation of time to peak plasma concentration following
administration of a single 850 mg tablet of metformin with food, compared to the same tablet strength administered fasting. The clinical relevance of these decreases is unknown.

**Distribution**

**Glyburide**

Sulfonylurea drugs are extensively bound to serum proteins. Displacement from protein binding sites by other drugs may lead to enhanced hypoglycemic action. *In vitro*, the protein binding exhibited by glyburide is predominantly non-ionic, whereas that of other sulfonylureas (chlorpropamide, tolbutamide, tolazamide) is predominantly ionic. Acidic drugs, such as phenylbutazone, warfarin, and salicylates, displace the ionic-binding sulfonylureas from serum proteins to a far greater extent than the non-ionic binding glyburide. It has not been shown that this difference in protein binding results in fewer drug-drug interactions with glyburide tablets in clinical use.

**Metformin Hydrochloride**

The apparent volume of distribution (V/F) of metformin following single oral doses of 850 mg averaged 654±358 L. Metformin is negligibly bound to plasma proteins. Metformin partitions into erythrocytes, most likely as a function of time. At usual clinical doses and dosing schedules of metformin, steady-state plasma concentrations of metformin are reached within 24 to 48 hours and are generally <1 µg/mL. During controlled clinical trials, maximum metformin plasma levels did not exceed 5 µg/mL, even at maximum doses.

**Metabolism and Elimination**

**Glyburide**

The decrease of glyburide in the serum of normal healthy individuals is biphasic; the terminal half-life is about 10 hours. The major metabolite of glyburide is the 4-trans-hydroxy derivative. A second metabolite, the 3-cis-hydroxy derivative, also occurs. These metabolites probably contribute no significant hypoglycemic action in humans since they are only weakly active (1/400 and 1/40 as active, respectively, as glyburide) in rabbits. Glyburide is excreted as metabolites in the bile and urine, approximately 50% by each route. This dual excretory pathway is qualitatively different from that of other sulfonylureas, which are excreted primarily in the urine.

**Metformin Hydrochloride**

Intravenous single-dose studies in normal subjects demonstrate that metformin is excreted unchanged in the urine and does not undergo hepatic metabolism (no metabolites have been
identified in humans) nor biliary excretion. Renal clearance (see Table 1) is approximately 3.5 times greater than creatinine clearance, which indicates that tubular secretion is the major route of metformin elimination. Following oral administration, approximately 90% of the absorbed drug is eliminated via the renal route within the first 24 hours, with a plasma elimination half-life of approximately 6.2 hours. In blood, the elimination half-life is approximately 17.6 hours, suggesting that the erythrocyte mass may be a compartment of distribution.

**Specific Populations**

**Patients With Type 2 Diabetes**

Multiple-dose studies with glyburide in patients with type 2 diabetes demonstrate drug level concentration-time curves similar to single-dose studies, indicating no buildup of drug in tissue depots.

In the presence of normal renal function, there are no differences between single- or multiple-dose pharmacokinetics of metformin between patients with type 2 diabetes and normal subjects (see Table 1), nor is there any accumulation of metformin in either group at usual clinical doses.

**Hepatic Impairment**

No pharmacokinetic studies have been conducted in patients with hepatic insufficiency for either glyburide or metformin (see PRECAUTIONS).

**Renal Impairment**

No information is available on the pharmacokinetics of glyburide in patients with renal insufficiency.

In patients with decreased renal function the plasma and blood half-life of metformin is prolonged and the renal clearance is decreased (see Table 1; also, see CONTRAINDICATIONS, WARNINGS, PRECAUTIONS, and DOSAGE AND ADMINISTRATION).
Geriatrics

There is no information on the pharmacokinetics of glyburide in elderly patients.

Limited data from controlled pharmacokinetic studies of metformin in healthy elderly subjects suggest that total plasma clearance is decreased, the half-life is prolonged, and $C_{\text{max}}$ is increased, when compared to healthy young subjects. From these data, it appears that the change in metformin pharmacokinetics with aging is primarily accounted for by a change in renal function (see Table 1; also see WARNINGS, PRECAUTIONS, and DOSAGE AND ADMINISTRATION).

Table 1: Select Mean (±SD) Metformin Pharmacokinetic Parameters Following Single or Multiple Oral Doses of Metformin

<table>
<thead>
<tr>
<th>Subject Groups: Metformin Dose</th>
<th>$C_{\text{max}}^b$ (µg/mL)</th>
<th>$T_{\text{max}}^c$ (hrs)</th>
<th>Renal Clearance (mL/min)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Healthy, nondiabetic adults:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>500 mg SD$^d$ (24)</td>
<td>1.03 (±0.33)</td>
<td>2.75 (±0.81)</td>
<td>600 (±132)</td>
</tr>
<tr>
<td>850 mg SD (74)$^e$</td>
<td>1.60 (±0.38)</td>
<td>2.64 (±0.82)</td>
<td>552 (±139)</td>
</tr>
<tr>
<td>850 mg t.i.d. for 19 doses$^f$ (9)</td>
<td>2.01 (±0.42)</td>
<td>1.79 (±0.94)</td>
<td>642 (±173)</td>
</tr>
<tr>
<td>Adults with type 2 diabetes:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>850 mg SD (23)</td>
<td>1.48 (±0.5)</td>
<td>3.32 (±1.08)</td>
<td>491 (±138)</td>
</tr>
<tr>
<td>850 mg t.i.d. for 19 doses$^f$ (9)</td>
<td>1.90 (±0.62)</td>
<td>2.01 (±1.22)</td>
<td>550 (±160)</td>
</tr>
<tr>
<td>Elderly$^g$, healthy nondiabetic adults:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>850 mg SD (12)</td>
<td>2.45 (±0.70)</td>
<td>2.71 (±1.05)</td>
<td>412 (±98)</td>
</tr>
<tr>
<td>Renal-impaired adults: 850 mg SD</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mild (CL$_{\text{cr}}^b$ 61-90 mL/min) (5)</td>
<td>1.86 (±0.52)</td>
<td>3.20 (±0.45)</td>
<td>384 (±122)</td>
</tr>
<tr>
<td>Moderate (CL$_{\text{cr}}$ 31-60 mL/min) (4)</td>
<td>4.12 (±1.83)</td>
<td>3.75 (±0.50)</td>
<td>108 (±57)</td>
</tr>
<tr>
<td>Severe (CL$_{\text{cr}}$ 10-30 mL/min) (6)</td>
<td>3.93 (±0.92)</td>
<td>4.01 (±1.10)</td>
<td>130 (±90)</td>
</tr>
</tbody>
</table>

$^a$ All doses given fasting except the first 18 doses of the multiple-dose studies

$^b$ Peak plasma concentration

$^c$ Time to peak plasma concentration

$^d$ SD=single dose

$^e$ Combined results (average means) of 5 studies: mean age 32 years (range 23-59 years)

$^f$ Kinetic study done following dose 19, given fasting

$^g$ Elderly subjects, mean age 71 years (range 65-81 years)

$^h$ CL$_{\text{cr}}$=creatinine clearance normalized to body surface area of 1.73 m$^2$

Pediatrics

After administration of a single oral GLUCOPHAGE® (metformin hydrochloride) 500 mg tablet with food, geometric mean metformin $C_{\text{max}}$ and AUC differed <5% between pediatric type 2 diabetic patients (12-16 years of age) and gender- and weight-matched healthy adults (20-45 years of age), all with normal renal function.
After administration of a single oral GLUCOVANCE tablet with food, dose-normalized geometric mean glyburide $C_{\text{max}}$ and AUC in pediatric patients with type 2 diabetes (11-16 years of age, n=28, mean body weight of 97 kg) differed $<6\%$ from historical values in healthy adults.

**Gender**

There is no information on the effect of gender on the pharmacokinetics of glyburide.

Metformin pharmacokinetic parameters did not differ significantly in subjects with or without type 2 diabetes when analyzed according to gender (males=19, females=16). Similarly, in controlled clinical studies in patients with type 2 diabetes, the antihyperglycemic effect of metformin was comparable in males and females.

**Race**

No information is available on race differences in the pharmacokinetics of glyburide.

No studies of metformin pharmacokinetic parameters according to race have been performed. In controlled clinical studies of metformin in patients with type 2 diabetes, the antihyperglycemic effect was comparable in whites (n=249), blacks (n=51), and Hispanics (n=24).

**Clinical Studies**

**Patients with Inadequate Glycemic Control on Diet and Exercise Alone**

In a 20-week, double-blind, multicenter U.S. clinical trial, a total of 806 drug-naive patients with type 2 diabetes, whose hyperglycemia was not adequately controlled with diet and exercise alone (baseline fasting plasma glucose [FPG] $<240$ mg/dL, baseline hemoglobin A$_{1c}$ [HbA$_{1c}$] between 7% and 11%), were randomized to receive initial therapy with placebo, 2.5 mg glyburide, 500 mg metformin, GLUCOVANCE 1.25 mg/250 mg, or GLUCOVANCE 2.5 mg/500 mg. After 4 weeks, the dose was progressively increased (up to the 8-week visit) to a maximum of 4 tablets daily as needed to reach a target FPG of 126 mg/dL. Trial data at 20 weeks are summarized in *Table 2*. 
Table 2: Placebo- and Active-Controlled Trial of GLUCOVANCE in Patients with Inadequate Glycemic Control on Diet and Exercise Alone: Summary of Trial Data at 20 Weeks

<table>
<thead>
<tr>
<th></th>
<th>Placebo</th>
<th>Glyburide 2.5 mg tablets</th>
<th>Metformin 500 mg tablets</th>
<th>GLUCOVANCE 1.25 mg/250 mg tablets</th>
<th>GLUCOVANCE 2.5 mg/500 mg tablets</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Mean Final Dose</strong></td>
<td>0 mg</td>
<td>5.3 mg</td>
<td>1317 mg</td>
<td>2.78 mg/557 mg</td>
<td>4.1 mg/824 mg</td>
</tr>
<tr>
<td><strong>Hemoglobin A₁c</strong></td>
<td>N=147</td>
<td>N=142</td>
<td>N=141</td>
<td>N=149</td>
<td>N=152</td>
</tr>
<tr>
<td>Baseline Mean (%)</td>
<td>8.14</td>
<td>8.14</td>
<td>8.23</td>
<td>8.22</td>
<td>8.20</td>
</tr>
<tr>
<td>Mean Change from Baseline</td>
<td>−0.21</td>
<td>−1.24</td>
<td>−1.03</td>
<td>−1.48</td>
<td>−1.53</td>
</tr>
<tr>
<td>Difference from Placebo</td>
<td>−1.02</td>
<td>−0.82</td>
<td>−1.26&lt;sup&gt;a&lt;/sup&gt;</td>
<td>−1.31&lt;sup&gt;a&lt;/sup&gt;</td>
<td></td>
</tr>
<tr>
<td>Difference from Glyburide</td>
<td></td>
<td></td>
<td>−0.24&lt;sup&gt;b&lt;/sup&gt;</td>
<td>−0.29&lt;sup&gt;b&lt;/sup&gt;</td>
<td></td>
</tr>
<tr>
<td>Difference from Metformin</td>
<td></td>
<td></td>
<td>−0.44&lt;sup&gt;b&lt;/sup&gt;</td>
<td>−0.49&lt;sup&gt;b&lt;/sup&gt;</td>
<td></td>
</tr>
<tr>
<td><strong>Fasting Plasma Glucose</strong></td>
<td>N=159</td>
<td>N=158</td>
<td>N=156</td>
<td>N=153</td>
<td>N=154</td>
</tr>
<tr>
<td>Baseline Mean FPG (mg/dL)</td>
<td>177.2</td>
<td>178.9</td>
<td>175.1</td>
<td>178</td>
<td>176.6</td>
</tr>
<tr>
<td>Mean Change from Baseline</td>
<td>4.6</td>
<td>−35.7</td>
<td>−21.2</td>
<td>−41.5</td>
<td>−40.1</td>
</tr>
<tr>
<td>Difference from Placebo</td>
<td>−40.3</td>
<td>−25.8</td>
<td>−46.1&lt;sup&gt;a&lt;/sup&gt;</td>
<td>−44.7&lt;sup&gt;a&lt;/sup&gt;</td>
<td></td>
</tr>
<tr>
<td>Difference from Glyburide</td>
<td></td>
<td></td>
<td>−5.8&lt;sup&gt;c&lt;/sup&gt;</td>
<td>−4.5&lt;sup&gt;c&lt;/sup&gt;</td>
<td></td>
</tr>
<tr>
<td>Difference from Metformin</td>
<td></td>
<td></td>
<td>−20.3&lt;sup&gt;c&lt;/sup&gt;</td>
<td>−18.9&lt;sup&gt;c&lt;/sup&gt;</td>
<td></td>
</tr>
<tr>
<td><strong>Body Weight Mean Change from Baseline</strong></td>
<td>−0.7 kg</td>
<td>+1.7 kg</td>
<td>−0.6 kg</td>
<td>+1.4 kg</td>
<td>+1.9 kg</td>
</tr>
<tr>
<td><strong>Final HbA₁c Distribution (%)</strong></td>
<td>N=147</td>
<td>N=142</td>
<td>N=141</td>
<td>N=149</td>
<td>N=152</td>
</tr>
<tr>
<td>&lt;7%</td>
<td>19.7%</td>
<td>59.9%</td>
<td>50.4%</td>
<td>66.4%</td>
<td>71.7%</td>
</tr>
<tr>
<td>≥7% and &lt;8%</td>
<td>37.4%</td>
<td>26.1%</td>
<td>29.8%</td>
<td>25.5%</td>
<td>19.1%</td>
</tr>
<tr>
<td>≥8%</td>
<td>42.9%</td>
<td>14.1%</td>
<td>19.9%</td>
<td>8.1%</td>
<td>9.2%</td>
</tr>
</tbody>
</table>

<sup>a</sup> p<0.001  
<sup>b</sup> p<0.05  
<sup>c</sup> p=NS

Treatment with GLUCOVANCE resulted in significantly greater reduction in HbA₁c and postprandial plasma glucose (PPG) compared to glyburide, metformin, or placebo. Also, GLUCOVANCE therapy resulted in greater reduction in FPG compared to glyburide, metformin, or placebo, but the differences from glyburide and metformin did not reach statistical significance.

Changes in the lipid profile associated with GLUCOVANCE treatment were similar to those seen with glyburide, metformin, and placebo.

The double-blind, placebo-controlled trial described above restricted enrollment to patients with HbA₁c <11% or FPG <240 mg/dL. Screened patients ineligible for the first trial because of HbA₁c and/or FPG exceeding these limits were treated directly with GLUCOVANCE 2.5 mg/500 mg in an open-label, uncontrolled protocol. In this study, 3 out of 173 patients (1.7%) discontinued because of inadequate therapeutic response. Across the group of 144...
patients who completed 26 weeks of treatment, mean HbA_1c was reduced from a baseline of 10.6% to 7.1%. The mean baseline FPG was 283 mg/dL and reduced to 164 and 161 mg/dL after 2 and 26 weeks, respectively. The mean final titrated dose of GLUCOVANCE was 7.85 mg/1569 mg (equivalent to approximately 3 GLUCOVANCE 2.5 mg/500 mg tablets per day).

Patients with Inadequate Glycemic Control on Sulfonylurea Alone

In a 16-week, double-blind, active-controlled U.S. clinical trial, a total of 639 patients with type 2 diabetes not adequately controlled (mean baseline HbA_1c 9.5%, mean baseline FPG 213 mg/dL) while being treated with at least one-half the maximum dose of a sulfonylurea (e.g., glyburide 10 mg, glipizide 20 mg) were randomized to receive glyburide (fixed dose, 20 mg), metformin (500 mg), GLUCOVANCE 2.5 mg/500 mg, or GLUCOVANCE 5 mg/500 mg. The doses of metformin and GLUCOVANCE were titrated to a maximum of 4 tablets daily as needed to achieve FPG <140 mg/dL. Trial data at 16 weeks are summarized in Table 3.

Table 3: GLUCOVANCE in Patients with Inadequate Glycemic Control on Sulfonylurea Alone: Summary of Trial Data at 16 Weeks

<table>
<thead>
<tr>
<th></th>
<th>Glyburide 5 mg tablets</th>
<th>Metformin 500 mg tablets</th>
<th>GLUCOVANCE 2.5 mg/500 mg tablets</th>
<th>GLUCOVANCE 5 mg/500 mg tablets</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Mean Final Dose</strong></td>
<td>20 mg</td>
<td>1840 mg</td>
<td>8.8 mg/1760 mg</td>
<td>17 mg/1740 mg</td>
</tr>
<tr>
<td><strong>Hemoglobin A_1c</strong></td>
<td>N=158</td>
<td>N=142</td>
<td>N=154</td>
<td>N=159</td>
</tr>
<tr>
<td>Baseline Mean (%)</td>
<td>9.63</td>
<td>9.51</td>
<td>9.43</td>
<td>9.44</td>
</tr>
<tr>
<td>Final Mean</td>
<td>9.61</td>
<td>9.82</td>
<td>7.92</td>
<td>7.91</td>
</tr>
<tr>
<td>Difference from Glyburide</td>
<td></td>
<td></td>
<td>−1.69^a</td>
<td>−1.70^a</td>
</tr>
<tr>
<td>Difference from Metformin</td>
<td></td>
<td></td>
<td>−1.90^a</td>
<td>−1.91^a</td>
</tr>
<tr>
<td><strong>Fasting Plasma Glucose</strong></td>
<td>N=163</td>
<td>N=152</td>
<td>N=160</td>
<td>N=160</td>
</tr>
<tr>
<td>Baseline Mean (mg/dL)</td>
<td>218.4</td>
<td>213.4</td>
<td>212.2</td>
<td>210.2</td>
</tr>
<tr>
<td>Final Mean</td>
<td>221.0</td>
<td>233.8</td>
<td>169.6</td>
<td>161.1</td>
</tr>
<tr>
<td>Difference from Glyburide</td>
<td></td>
<td></td>
<td>−51.3^a</td>
<td>−59.9^a</td>
</tr>
<tr>
<td>Difference from Metformin</td>
<td></td>
<td></td>
<td>−64.2^a</td>
<td>−72.7^a</td>
</tr>
<tr>
<td><strong>Body Weight Mean Change from Baseline</strong></td>
<td>+0.43 kg</td>
<td>−2.76 kg</td>
<td>+0.75 kg</td>
<td>+0.47 kg</td>
</tr>
<tr>
<td><strong>Final HbA_1c Distribution (%)</strong></td>
<td>N=158</td>
<td>N=142</td>
<td>N=154</td>
<td>N=159</td>
</tr>
<tr>
<td>&lt;7%</td>
<td>2.5%</td>
<td>2.8%</td>
<td>24.7%</td>
<td>22.6%</td>
</tr>
<tr>
<td>≥7% and &lt;8%</td>
<td>9.5%</td>
<td>11.3%</td>
<td>33.1%</td>
<td>37.1%</td>
</tr>
<tr>
<td>≥8%</td>
<td>88%</td>
<td>85.9%</td>
<td>42.2%</td>
<td>40.3%</td>
</tr>
</tbody>
</table>

^ p<0.001
After 16 weeks, there was no significant change in the mean HbA1c in patients randomized to glyburide or metformin therapy. Treatment with GLUCOVANCE at doses up to 20 mg/2000 mg per day resulted in significant lowering of HbA1c, FPG, and PPG from baseline compared to glyburide or metformin alone.

**Addition of Thiazolidinediones to GLUCOVANCE Therapy**

In a 24-week, double-blind, multicenter U.S. clinical trial, patients with type 2 diabetes not adequately controlled on current oral antihyperglycemic therapy (either monotherapy or combination therapy) were first switched to open label GLUCOVANCE 2.5 mg/500 mg tablets and titrated to a maximum daily dose of 10 mg/2000 mg. A total of 365 patients inadequately controlled (HbA1c >7.0% and ≤10%) after 10 to 12 weeks of a daily GLUCOVANCE dose of at least 7.5 mg/1500 mg were randomized to receive add-on therapy with rosiglitazone 4 mg or placebo once daily. After 8 weeks, the rosiglitazone dose was increased to a maximum of 8 mg daily as needed to reach a target mean daily glucose of 126 mg/dL or HbA1c <7%. Trial data at 24 weeks or the last prior visit are summarized in Table 4.

**Table 4: Effects of Adding Rosiglitazone or Placebo in Patients Treated with GLUCOVANCE in a 24-Week Trial**

<table>
<thead>
<tr>
<th>Mean Final Dose</th>
<th>Placebo + GLUCOVANCE</th>
<th>Rosiglitazone + GLUCOVANCE</th>
</tr>
</thead>
<tbody>
<tr>
<td>GLUCOVANCE</td>
<td>10 mg/1992 mg</td>
<td>9.6 mg/1914 mg</td>
</tr>
<tr>
<td>Rosiglitazone</td>
<td>0 mg</td>
<td>7.4 mg</td>
</tr>
<tr>
<td>Hemoglobin A1c</td>
<td>N=178</td>
<td>N=177</td>
</tr>
<tr>
<td>Baseline Mean (%)</td>
<td>8.09</td>
<td>8.14</td>
</tr>
<tr>
<td>Final Mean</td>
<td>8.21</td>
<td>7.23</td>
</tr>
<tr>
<td>Difference from Placebo*</td>
<td>−1.02b</td>
<td></td>
</tr>
<tr>
<td>Fasting Plasma Glucose</td>
<td>N=181</td>
<td>N=176</td>
</tr>
<tr>
<td>Baseline Mean (mg/dL)</td>
<td>173.1</td>
<td>178.4</td>
</tr>
<tr>
<td>Final Mean</td>
<td>181.4</td>
<td>136.3</td>
</tr>
<tr>
<td>Difference from Placebo*</td>
<td>−48.5b</td>
<td></td>
</tr>
<tr>
<td>Body Weight Mean Change from Baseline</td>
<td>+0.03 kg</td>
<td>+3.03 kg</td>
</tr>
<tr>
<td>Final HbA1c Distribution (%)</td>
<td>N=178</td>
<td>N=177</td>
</tr>
<tr>
<td>&lt;7%</td>
<td>13.5%</td>
<td>42.4%</td>
</tr>
<tr>
<td>≥7% and &lt;8%</td>
<td>32.0%</td>
<td>38.4%</td>
</tr>
<tr>
<td>≥8%</td>
<td>54.5%</td>
<td>19.2%</td>
</tr>
</tbody>
</table>

* Adjusted for the baseline mean difference

b p<0.001
For patients who did not achieve adequate glycemic control on GLUCOVANCE, the addition of rosiglitazone, compared to placebo, resulted in significant lowering of HbA1c and FPG.

**INDICATIONS AND USAGE**

GLUCOVANCE (Glyburide and Metformin HCl) Tablets is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

**CONTRAINDICATIONS**

GLUCOVANCE is contraindicated in patients with:

1. Severe renal impairment (eGFR below 30 mL/min/1.73m²) (see WARNINGS and PRECAUTIONS).
2. Known hypersensitivity to metformin hydrochloride or glyburide.
3. Acute or chronic metabolic acidosis, including diabetic ketoacidosis, with or without coma. Diabetic ketoacidosis should be treated with insulin.
4. Concomitant administration of bosentan.

**WARNINGS**

**Metformin Hydrochloride**

**WARNING: LACTIC ACIDOSIS**

Post-marketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias. The onset of metformin-associated lactic acidosis is often subtle, accompanied only by nonspecific symptoms such as malaise, myalgias, respiratory distress, somnolence, and abdominal pain. Metformin-associated lactic acidosis was characterized by elevated blood lactate levels (>5 mmol/Liter), anion gap acidosis (without evidence of ketonuria or ketonemia), an increased lactate/pyruvate ratio; and metformin plasma levels generally >5 mcg/mL (see PRECAUTIONS).

Risk factors for metformin-associated lactic acidosis include renal impairment, concomitant use of certain drugs (e.g., carbonic anhydrase inhibitors such as topiramate), age 65 years old or greater, having a radiological study with contrast, surgery and other procedures, hypoxic states (e.g. acute congestive heart failure), excessive alcohol intake, and hepatic impairment.
Steps to reduce the risk of and manage metformin-associated lactic acidosis in these high risk groups are provided (see DOSAGE AND ADMINISTRATION, CONTRAINDICATIONS, and PRECAUTIONS).

If metformin-associated lactic acidosis is suspected, immediately discontinue GLUCOVANCE and institute general supportive measures in a hospital setting. Prompt hemodialysis is recommended (see PRECAUTIONS).

SPECIAL WARNING ON INCREASED RISK OF CARDIOVASCULAR MORTALITY

The administration of oral hypoglycemic drugs has been reported to be associated with increased cardiovascular mortality as compared to treatment with diet alone or diet plus insulin. This warning is based on the study conducted by the University Group Diabetes Program (UGDP), a long-term prospective clinical trial designed to evaluate the effectiveness of glucose-lowering drugs in preventing or delaying vascular complications in patients with non-insulin-dependent diabetes. The study involved 823 patients who were randomly assigned to 1 of 4 treatment groups (Diabetes 19 (Suppl. 2):747-830, 1970).

UGDP reported that patients treated for 5 to 8 years with diet plus a fixed dose of tolbutamide (1.5 g per day) had a rate of cardiovascular mortality approximately 2½ times that of patients treated with diet alone. A significant increase in total mortality was not observed, but the use of tolbutamide was discontinued based on the increase in cardiovascular mortality, thus limiting the opportunity for the study to show an increase in overall mortality. Despite controversy regarding the interpretation of these results, the findings of the UGDP study provide an adequate basis for this warning. The patient should be informed of the potential risks and benefits of glyburide and of alternative modes of therapy.

Although only 1 drug in the sulfonylurea class (tolbutamide) was included in this study, it is prudent from a safety standpoint to consider that this warning may also apply to other hypoglycemic drugs in this class, in view of their close similarities in mode of action and chemical structure.

PRECAUTIONS

GLUCOVANCE

Lactic Acidosis
There have been post-marketing cases of metformin-associated lactic acidosis, including fatal cases. These cases had a subtle onset and were accompanied by nonspecific symptoms such as malaise, myalgias, abdominal pain, respiratory distress, or increased somnolence; however, hypotension and resistant bradycardias have occurred with severe acidosis. Metformin-associated lactic acidosis was characterized by elevated blood lactate concentrations (>5 mmol/L), anion gap acidosis (without evidence of ketonuria or ketonemia), and an increased lactate:pyruvate ratio; metformin plasma levels were generally >5 mcg/mL. Metformin decreases liver uptake of lactate increasing lactate blood levels which may increase the risk of lactic acidosis, especially in patients at risk.

If metformin-associated lactic acidosis is suspected, general supportive measures should be instituted promptly in a hospital setting, along with immediate discontinuation of GLUCOVANCE. In GLUCOVANCE treated patients with a diagnosis or strong suspicion of lactic acidosis, prompt hemodialysis is recommended to correct the acidosis and remove accumulated metformin (metformin hydrochloride is dialyzable with a clearance of up to 170 mL/min under good hemodynamic conditions). Hemodialysis has often resulted in reversal of symptoms and recovery.

Educate patients and their families about the symptoms of lactic acidosis and if these symptoms occur instruct them to discontinue GLUCOVANCE and report these symptoms to their healthcare provider.

For each of the known and possible risk factors for metformin-associated lactic acidosis, recommendations to reduce the risk of and manage metformin-associated lactic acidosis are provided below:

- **Renal Impairment**—The postmarketing metformin-associated lactic acidosis cases primarily occurred in patients with significant renal impairment.

The risk of metformin accumulation and metformin-associated lactic acidosis increases with the severity of renal impairment because metformin is substantially excreted by the kidney. Clinical recommendations based upon the patient’s renal function include (see DOSAGE AND ADMINISTRATION, CLINICAL PHARMACOLOGY):

- Before initiating GLUCOVANCE, obtain an estimated glomerular filtration rate (eGFR).
- GLUCOVANCE is contraindicated in patients with an eGFR less than 30 mL/min/1.73 m² (see CONTRAINDICATIONS).
Initiation of GLUCOVANCE is not recommended in patients with eGFR between 30-45 mL/min/1.73 m².

Obtain an eGFR at least annually in all patient taking GLUCOVANCE. In patients at risk for the development of renal impairment (e.g., the elderly), renal function should be assessed more frequently.

In patients taking GLUCOVANCE whose eGFR falls below 45 mL/min/1.73 m², assess the benefit and risk of continuing therapy.

• **Drug interactions**—The concomitant use of GLUCOVANCE with specific drugs may increase the risk of metformin-associated lactic acidosis: those that impair renal function, result in significant hemodynamic change, interfere with acid-base balance, or increase metformin accumulation. Consider more frequent monitoring of patients.

• **Age 65 or Greater**—The risk of metformin-associated lactic acidosis increases with the patient’s age because elderly patients have a greater likelihood of having hepatic, renal, or cardiac impairment than younger patients. Assess renal function more frequently in elderly patients.

• **Radiologic studies with contrast**—Administration of intravascular iodinated contrast agents in metformin-treated patients has led to an acute decrease in renal function and the occurrence of lactic acidosis. Stop GLUCOVANCE at the time of, or prior to, an iodinated contrast imaging procedure in patients with an eGFR between 30 and 60 mL/min/1.73 m²; in patients with a history of hepatic impairment, alcoholism or heart failure, or in patients who will be administered intra-arterial iodinated contrast. Reevaluate eGFR 48 hours after the imaging procedure, and restart GLUCOVANCE if renal function is stable.

• **Surgery and other procedures**—Withholding of food and fluids during surgical or other procedures may increase the risk for volume depletion, hypotension, and renal impairment. GLUCOVANCE should be temporarily discontinued while patients have restricted food and fluid intake.

• **Hypoxic states**—Several of the postmarketing cases of metformin-associated lactic acidosis occurred in the setting of acute congestive heart failure (particularly when accompanied by hypoperfusion and hypoxemia). Cardiovascular collapse (shock), acute myocardial infarction, sepsis, and other conditions associated with hypoxemia have been associated with lactic acidosis and may cause prerenal azotemia. When such an event occurs, discontinue GLUCOVANCE.

• **Excessive Alcohol intake**—Alcohol is known to potentiate the effect of metformin on lactate metabolism. Patients, therefore, should be warned against excessive alcohol intake, acute or chronic, while receiving GLUCOVANCE.
• **Hepatic impairment**—Patients with hepatic impairment have developed cases of metformin-associated lactic acidosis. This may be due to impaired lactate clearance resulting in higher lactate blood levels. Therefore, avoid use of GLUCOVANCE in patients with clinical or laboratory evidence of hepatic disease.

**Hypoglycemia**

GLUCOVANCE is capable of producing hypoglycemia or hypoglycemic symptoms, therefore, proper patient selection, dosing, and instructions are important to avoid potential hypoglycemic episodes. The risk of hypoglycemia is increased when caloric intake is deficient, when strenuous exercise is not compensated by caloric supplementation, or during concomitant use with other glucose-lowering agents or ethanol. Renal or hepatic insufficiency may cause elevated drug levels of both glyburide and metformin hydrochloride, and the hepatic insufficiency may also diminish gluconeogenic capacity, both of which increase the risk of hypoglycemic reactions. Elderly, debilitated, or malnourished patients and those with adrenal or pituitary insufficiency or alcohol intoxication are particularly susceptible to hypoglycemic effects. Hypoglycemia may be difficult to recognize in the elderly and people who are taking beta-adrenergic blocking drugs.

**Glyburide**

**Hemolytic anemia**

Treatment of patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency with sulfonylurea agents can lead to hemolytic anemia. Because GLUCOVANCE belongs to the class of sulfonylurea agents, caution should be used in patients with G6PD deficiency and a non-sulfonylurea alternative should be considered. In postmarketing reports, hemolytic anemia has also been reported in patients who did not have known G6PD deficiency.

**Metformin Hydrochloride**

**Vitamin B12 levels**

In controlled clinical trials with metformin of 29 weeks duration, a decrease to subnormal levels of previously normal serum vitamin B₁₂, without clinical manifestations, was observed in approximately 7% of patients. Such decrease, possibly due to interference with B₁₂ absorption from the B₁₂-intrinsic factor complex is, however, very rarely associated with anemia and appears to be rapidly reversible with discontinuation of metformin or vitamin B₁₂ supplementation. Measurement of hematologic parameters on an annual basis is advised in
patients on metformin and any apparent abnormalities should be appropriately investigated and managed (see PRECAUTIONS: Laboratory Tests).

Certain individuals (those with inadequate vitamin $\text{B}_{12}$ or calcium intake or absorption) appear to be predisposed to developing subnormal vitamin $\text{B}_{12}$ levels. In these patients, routine serum vitamin $\text{B}_{12}$ measurements at 2- to 3-year intervals may be useful.

**Macrovascular Outcomes**

There have been no clinical studies establishing conclusive evidence of macrovascular risk reduction with GLUCOVANCE or any other antidiabetic drug.

**Addition of Thiazolidinediones to GLUCOVANCE Therapy**

**Hypoglycemia**

Patients receiving GLUCOVANCE in combination with a thiazolidinedione may be at risk for hypoglycemia.

**Weight gain**

Weight gain was seen with the addition of rosiglitazone to GLUCOVANCE, similar to that reported for thiazolidinedione therapy alone.

**Hepatic effects**

When a thiazolidinedione is used in combination with GLUCOVANCE, periodic monitoring of liver function tests should be performed in compliance with the labeled recommendations for the thiazolidinedione.

**Information for Patients**

**GLUCOVANCE**

Patients should be informed of the potential risks and benefits of GLUCOVANCE and alternative modes of therapy. They should also be informed about the importance of adherence to dietary instructions; a regular exercise program; and regular testing of blood glucose, glycosylated hemoglobin, renal function, and hematologic parameters.

The risks of lactic acidosis associated with metformin therapy, its symptoms, and conditions that predispose to its development, as noted in the WARNINGS and PRECAUTIONS sections, should be explained to patients. Patients should be advised to discontinue GLUCOVANCE
immediately and promptly notify their health practitioner if unexplained hyperventilation, myalgia, malaise, unusual somnolence, or other nonspecific symptoms occur. Once a patient is stabilized on any dose level of GLUCOVANCE, gastrointestinal symptoms, which are common during initiation of metformin therapy, are unlikely to be drug related. Later occurrence of gastrointestinal symptoms could be due to lactic acidosis or other serious disease.

The risks of hypoglycemia, its symptoms and treatment, and conditions that predispose to its development should be explained to patients and responsible family members.

Patients should be counseled against excessive alcohol intake, either acute or chronic, while receiving GLUCOVANCE. (See Patient Information printed below.)

**Laboratory Tests**

Periodic fasting blood glucose (FBG) and HbA₁c measurements should be performed to monitor therapeutic response.

Initial and periodic monitoring of hematologic parameters (e.g., hemoglobin/hematocrit and red blood cell indices) and renal function (serum creatinine) should be performed, at least on an annual basis. While megaloblastic anemia has rarely been seen with metformin therapy, if this is suspected, vitamin B₁₂ deficiency should be excluded.

Instruct patients to inform their doctor that they are taking GLUCOVANCE prior to any surgical or radiological procedure, as temporary discontinuation of GLUCOVANCE may be required until renal function has been confirmed to be normal (see PRECAUTIONS).

**Drug Interactions**

**GLUCOVANCE**

Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. These drugs include thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. When such drugs are administered to a patient receiving GLUCOVANCE, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving GLUCOVANCE, the patient should be observed closely for hypoglycemia. Metformin is negligibly bound to plasma proteins and is, therefore, less likely to interact with highly protein-bound drugs such as salicylates, sulfonamides, chloramphenicol, and probenecid as compared to sulfonylureas, which are extensively bound to serum proteins.
**Glyburide**

The hypoglycemic action of sulfonylureas may be potentiated by certain drugs, including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta-adrenergic blocking agents. When such drugs are administered to a patient receiving GLUCOVANCE, the patient should be observed closely for hypoglycemia. When such drugs are withdrawn from a patient receiving GLUCOVANCE, the patient should be observed closely for loss of blood glucose control.

An increased risk of liver enzyme elevations was observed in patients receiving glyburide concomitantly with bosentan. Therefore, concomitant administration of GLUCOVANCE and bosentan is contraindicated.

A possible interaction between glyburide and ciprofloxacin, a fluoroquinolone antibiotic, has been reported, resulting in a potentiation of the hypoglycemic action of glyburide. The mechanism for this interaction is not known.

A potential interaction between oral miconazole and oral hypoglycemic agents leading to severe hypoglycemia has been reported. Whether this interaction also occurs with the intravenous, topical, or vaginal preparations of miconazole is not known.

Colesevelam: Concomitant administration of colesevelam and glyburide resulted in reductions in glyburide AUC and $C_{\text{max}}$ of 32% and 47%, respectively. The reductions in glyburide AUC and $C_{\text{max}}$ were 20% and 15%, respectively, when administered 1 hour before, and not significantly changed ($\sim$7% and 4%, respectively) when administered 4 hours before colesevelam.

**Metformin Hydrochloride**

**Furosemide**

A single-dose, metformin-furosemide drug interaction study in healthy subjects demonstrated that pharmacokinetic parameters of both compounds were affected by coadministration. Furosemide increased the metformin plasma and blood $C_{\text{max}}$ by 22% and blood AUC by 15%, without any significant change in metformin renal clearance. When administered with metformin, the $C_{\text{max}}$ and AUC of furosemide were 31% and 12% smaller, respectively, than when administered alone, and the terminal half-life was decreased by 32%, without any significant change in furosemide renal clearance. No information is available about the interaction of metformin and furosemide when coadministered chronically.
**Nifedipine**

A single-dose, metformin-nifedipine drug interaction study in normal healthy volunteers demonstrated that coadministration of nifedipine increased plasma metformin $C_{max}$ and AUC by 20% and 9%, respectively, and increased the amount excreted in the urine. $T_{max}$ and half-life were unaffected. Nifedipine appears to enhance the absorption of metformin. Metformin had minimal effects on nifedipine.

**Drugs that reduce metformin clearance**

Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transport-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors such as ranolazine, vandetanib, dolutegravir, and cimetidine) could increase systemic exposure to metformin and may increase the accumulation of metformin and the risk for lactic acidosis. Consider the benefits and risks of concomitant use. Such interaction between metformin and oral cimetidine has been observed in normal healthy volunteers in both single- and multiple-dose, metformin-cimetidine drug interaction studies, with a 60% increase in peak metformin plasma and whole blood concentrations and a 40% increase in plasma and whole blood metformin AUC. There was no change in elimination half-life in the single-dose study. Metformin had no effect on cimetidine pharmacokinetics.

In healthy volunteers, the pharmacokinetics of metformin and propranolol, and metformin and ibuprofen were not affected when coadministered in single-dose interaction studies.

Metformin is negligibly bound to plasma proteins and is, therefore, less likely to interact with highly protein-bound drugs such as salicylates, sulfonamides, chloramphenicol, and probenecid, as compared to the sulfonylureas, which are extensively bound to serum proteins.

**Carbonic Anhydrase Inhibitors**

Topiramate or other carbonic anhydrase inhibitors (e.g., zonisamide, acetazolamide or dichlorphenamid) frequently causes a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis. Concomitant use of these drugs with GLUCOVANCE may increase the risk for lactic acidosis. Consider more frequent monitoring of these patients.

**Alcohol**

Alcohol is known to potentiate the effects of metformin on lactate metabolism. Warn patients against excessive alcohol intake while receiving GLUCOVANCE.
Carcinogenesis, Mutagenesis, Impairment of Fertility

No animal studies have been conducted with the combined products in GLUCOVANCE. The following data are based on findings in studies performed with the individual products.

Glyburide

Studies in rats with glyburide alone at doses up to 300 mg/kg/day (approximately 145 times the maximum recommended human daily [MRHD] dose of 20 mg for the glyburide component of GLUCOVANCE based on body surface area comparisons) for 18 months revealed no carcinogenic effects. In a 2-year oncogenicity study of glyburide in mice, there was no evidence of treatment-related tumors.

There was no evidence of mutagenic potential of glyburide alone in the following in vitro tests: Salmonella microsome test (Ames test) and in the DNA damage/alkaline elution assay.

Metformin Hydrochloride

Long-term carcinogenicity studies were performed with metformin alone in rats (dosing duration of 104 weeks) and mice (dosing duration of 91 weeks) at doses up to and including 900 mg/kg/day and 1500 mg/kg/day, respectively. These doses are both approximately 4 times the MRHD dose of 2000 mg of the metformin component of GLUCOVANCE based on body surface area comparisons. No evidence of carcinogenicity with metformin alone was found in either male or female mice. Similarly, there was no tumorigenic potential observed with metformin alone in male rats. There was, however, an increased incidence of benign stromal uterine polyps in female rats treated with 900 mg/kg/day of metformin alone.

There was no evidence of a mutagenic potential of metformin alone in the following in vitro tests: Ames test (S. typhimurium), gene mutation test (mouse lymphoma cells), or chromosomal aberrations test (human lymphocytes). Results in the in vivo mouse micronucleus test were also negative.

Fertility of male or female rats was unaffected by metformin alone when administered at doses as high as 600 mg/kg/day, which is approximately 3 times the MRHD dose of the metformin component of GLUCOVANCE based on body surface area comparisons.
Pregnancy

Teratogenic Effects: Pregnancy Category B

Recent information strongly suggests that abnormal blood glucose levels during pregnancy are associated with a higher incidence of congenital abnormalities. Most experts recommend that insulin be used during pregnancy to maintain blood glucose as close to normal as possible. Because animal reproduction studies are not always predictive of human response, GLUCOVANCE should not be used during pregnancy unless clearly needed. (See below.)

There are no adequate and well-controlled studies in pregnant women with GLUCOVANCE or its individual components. No animal studies have been conducted with the combined products in GLUCOVANCE. The following data are based on findings in studies performed with the individual products.

**Glyburide**

Reproduction studies were performed in rats and rabbits at doses up to 500 times the MRHD dose of 20 mg of the glyburide component of GLUCOVANCE based on body surface area comparisons and revealed no evidence of impaired fertility or harm to the fetus due to glyburide.

**Metformin Hydrochloride**

Metformin alone was not teratogenic in rats or rabbits at doses up to 600 mg/kg/day. This represents an exposure of about 2 and 6 times the MRHD dose of 2000 mg of the metformin component of GLUCOVANCE based on body surface area comparisons for rats and rabbits, respectively. Determination of fetal concentrations demonstrated a partial placental barrier to metformin.

**Nonteratogenic Effects**

Prolonged severe hypoglycemia (4-10 days) has been reported in neonates born to mothers who were receiving a sulfonylurea drug at the time of delivery. This has been reported more frequently with the use of agents with prolonged half-lives. It is not recommended that GLUCOVANCE be used during pregnancy. However, if it is used, GLUCOVANCE should be discontinued at least 2 weeks before the expected delivery date. (See Pregnancy: Teratogenic Effects: Pregnancy Category B.)

**Nursing Mothers**

Although it is not known whether glyburide is excreted in human milk, some sulfonylurea drugs are known to be excreted in human milk. Studies in lactating rats show that metformin is
excreted into milk and reaches levels comparable to those in plasma. Similar studies have not been conducted in nursing mothers. Because the potential for hypoglycemia in nursing infants may exist, a decision should be made whether to discontinue nursing or to discontinue GLUCOVANCE, taking into account the importance of the drug to the mother. If GLUCOVANCE is discontinued, and if diet alone is inadequate for controlling blood glucose, insulin therapy should be considered.

**Pediatric Use**

The safety and efficacy of GLUCOVANCE were evaluated in an active-controlled, double-blind, 26-week randomized trial involving a total of 167 pediatric patients (ranging from 9-16 years of age) with type 2 diabetes. GLUCOVANCE was not shown statistically to be superior to either metformin or glyburide with respect to reducing HbA1c from baseline (see Table 5). No unexpected safety findings were associated with GLUCOVANCE in this trial.

**Table 5: HbA1c (Percent) Change From Baseline at 26 Weeks: Pediatric Study**

<table>
<thead>
<tr>
<th></th>
<th>Glyburide 2.5 mg tablets</th>
<th>Metformin 500 mg tablets</th>
<th>GLUCOVANCE 1.25 mg/250 mg tablets</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean Final Dose</td>
<td>6.5 mg</td>
<td>1500 mg</td>
<td>3.1 mg/623 mg</td>
</tr>
<tr>
<td>Hemoglobin A1c Baseline</td>
<td>N=49</td>
<td>N=54</td>
<td>N=57</td>
</tr>
<tr>
<td>Baseline Mean (%)</td>
<td>7.70</td>
<td>7.99</td>
<td>7.85</td>
</tr>
<tr>
<td>Mean Change from Baseline</td>
<td>−0.96</td>
<td>−0.48</td>
<td>−0.80</td>
</tr>
<tr>
<td>Difference from Metformin</td>
<td></td>
<td></td>
<td>−0.32</td>
</tr>
<tr>
<td>Difference from Glyburide</td>
<td></td>
<td></td>
<td>+0.16</td>
</tr>
</tbody>
</table>

**Geriatric Use**

Of the 642 patients who received GLUCOVANCE in double-blind clinical studies, 23.8% were 65 and older while 2.8% were 75 and older. Of the 1302 patients who received GLUCOVANCE in open-label clinical studies, 20.7% were 65 and older while 2.5% were 75 and older. No overall differences in effectiveness or safety were observed between these patients and younger patients, and other reported clinical experience has not identified differences in response between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.

In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy and the higher risk of lactic acidosis. Assess renal function more frequently in elderly patients (see also WARNINGS, PRECAUTIONS, and DOSAGE AND ADMINISTRATION).
ADVERSE REACTIONS

GLUCOVANCE

In double-blind clinical trials involving GLUCOVANCE as initial therapy or as second-line therapy, a total of 642 patients received GLUCOVANCE, 312 received metformin therapy, 324 received glyburide therapy, and 161 received placebo. The percent of patients reporting events and types of adverse events reported in clinical trials of GLUCOVANCE (all strengths) as initial therapy and second-line therapy are listed in Table 6.

Table 6: Most Common Clinical Adverse Events (>5%) in Double-Blind Clinical Studies of GLUCOVANCE Used as Initial or Second-Line Therapy

<table>
<thead>
<tr>
<th>Adverse Event</th>
<th>Placebo N=161</th>
<th>Glyburide N=324</th>
<th>Metformin N=312</th>
<th>GLUCOVANCE N=642</th>
</tr>
</thead>
<tbody>
<tr>
<td>Upper respiratory infection</td>
<td>22 (13.7)</td>
<td>57 (17.6)</td>
<td>51 (16.3)</td>
<td>111 (17.3)</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>9 (5.6)</td>
<td>20 (6.2)</td>
<td>64 (20.5)</td>
<td>109 (17.0)</td>
</tr>
<tr>
<td>Headache</td>
<td>17 (10.6)</td>
<td>37 (11.4)</td>
<td>29 (9.3)</td>
<td>57 (8.9)</td>
</tr>
<tr>
<td>Nausea/vomiting</td>
<td>10 (6.2)</td>
<td>17 (5.2)</td>
<td>38 (12.2)</td>
<td>49 (7.6)</td>
</tr>
<tr>
<td>Abdominal pain</td>
<td>6 (3.7)</td>
<td>10 (3.1)</td>
<td>25 (8.0)</td>
<td>44 (6.9)</td>
</tr>
<tr>
<td>Dizziness</td>
<td>7 (4.3)</td>
<td>18 (5.6)</td>
<td>12 (3.8)</td>
<td>35 (5.5)</td>
</tr>
</tbody>
</table>

In a controlled clinical trial of rosiglitazone versus placebo in patients treated with GLUCOVANCE (n=365), 181 patients received GLUCOVANCE with rosiglitazone and 184 received GLUCOVANCE with placebo.

Edema was reported in 7.7% (14/181) of patients treated with rosiglitazone compared to 2.2% (4/184) of patients treated with placebo. A mean weight gain of 3 kg was observed in rosiglitazone-treated patients.

Disulfiram-like reactions have very rarely been reported in patients treated with glyburide tablets.

Hypoglycemia

In controlled clinical trials of GLUCOVANCE there were no hypoglycemic episodes requiring medical intervention and/or pharmacologic therapy; all events were managed by the patients. The incidence of reported symptoms of hypoglycemia (such as dizziness, shakiness, sweating, and hunger), in the initial therapy trial of GLUCOVANCE are summarized in Table 7. The frequency of hypoglycemic symptoms in patients treated with GLUCOVANCE 1.25 mg/250 mg was highest in patients with a baseline HbA1c <7%, lower in those with a baseline HbA1c of
between 7% and 8%, and was comparable to placebo and metformin in those with a baseline HbA1c >8%. For patients with a baseline HbA1c between 8% and 11% treated with GLUCOVANCE 2.5 mg/500 mg as initial therapy, the frequency of hypoglycemic symptoms was 30% to 35%. As second-line therapy in patients inadequately controlled on sulfonylurea alone, approximately 6.8% of all patients treated with GLUCOVANCE experienced hypoglycemic symptoms. When rosiglitazone was added to GLUCOVANCE therapy, 22% of patients reported 1 or more fingerstick glucose measurements ≤50 mg/dL compared to 3.3% of placebo-treated patients. All hypoglycemic events were managed by the patients and only 1 patient discontinued for hypoglycemia. (See PRECAUTIONS: General: Addition of Thiazolidinediones to GLUCOVANCE Therapy.)

Gastrointestinal Reactions

The incidence of gastrointestinal (GI) side effects (diarrhea, nausea/vomiting, and abdominal pain) in the initial therapy trial are summarized in Table 7. Across all GLUCOVANCE trials, GI symptoms were the most common adverse events with GLUCOVANCE and were more frequent at higher dose levels. In controlled trials, <2% of patients discontinued GLUCOVANCE therapy due to GI adverse events.

<table>
<thead>
<tr>
<th>Variable</th>
<th>Placebo N=161</th>
<th>Glyburide Tablets N=160</th>
<th>Metformin Tablets N=159</th>
<th>GLUCOVANCE 1.25 mg/250 mg Tablets N=158</th>
<th>GLUCOVANCE 2.5 mg/500 mg Tablets N=162</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean Final Dose</td>
<td>0 mg</td>
<td>5.3 mg</td>
<td>1317 mg</td>
<td>2.78 mg/557 mg</td>
<td>4.1 mg/824 mg</td>
</tr>
<tr>
<td>Number (%) of patients with symptoms of hypoglycemia</td>
<td>5 (3.1)</td>
<td>34 (21.3)</td>
<td>5 (3.1)</td>
<td>18 (11.4)</td>
<td>61 (37.7)</td>
</tr>
<tr>
<td>Number (%) of patients with gastrointestinal adverse events</td>
<td>39 (24.2)</td>
<td>38 (23.8)</td>
<td>69 (43.3)</td>
<td>50 (31.6)</td>
<td>62 (38.3)</td>
</tr>
</tbody>
</table>

Metformin Hydrochloride

Cholestatic, hepatocellular, and mixed hepatocellular liver injury have been reported with postmarketing use of metformin.

Glyburide
Gastrointestinal Reactions

Cholestatic jaundice and hepatitis may occur rarely which may progress to liver failure; the drug should be discontinued if this occurs. Liver function abnormalities, including isolated transaminase elevations, have been reported.

Dermatologic Reactions

Allergic skin reactions, eg, pruritus, erythema, urticaria, and morbilliform or maculopapular eruptions, occur in 1.5% of glyburide-treated patients. These may be transient and may disappear despite continued use; if skin reactions persist, the drug should be discontinued.

Postmarketing Adverse Reactions

The following adverse reactions have been identified during post-approval use. Because these reactions are reported voluntarily from a population of uncertain size, it is generally not possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Allergic: Angioedema, arthralgia, myalgia, and vasculitis have been reported.

Dermatologic: Porphyria cutanea tarda and photosensitivity reactions have been reported with sulfonylureas.

Hematologic: Leukopenia, agranulocytosis, thrombocytopenia, which occasionally may present as purpura, hemolytic anemia, aplastic anemia, and pancytopenia, have been reported with sulfonylureas.

Metabolic: Hepatic porphyria reactions have been reported with sulfonylureas; however, these have not been reported with glyburide. Disulfiram-like reactions have been reported very rarely with glyburide. Cases of hyponatremia have been reported with glyburide and all other sulfonylureas, most often in patients who are on other medications or have medical conditions known to cause hyponatremia or increase release of antidiuretic hormone.

Other Reactions: Changes in accommodation and/or blurred vision have been reported with glyburide and other sulfonylureas. These are thought to be related to fluctuation in glucose levels.

OVERDOSAGE

Glyburide

Overdosage of sulfonylureas, including glyburide tablets, can produce hypoglycemia. Mild hypoglycemic symptoms, without loss of consciousness or neurological findings, should be treated aggressively with oral glucose and adjustments in drug dosage and/or meal patterns. Close monitoring should continue until the physician is assured that the patient is out of danger.
Severe hypoglycemic reactions with coma, seizure, or other neurological impairment occur infrequently, but constitute medical emergencies requiring immediate hospitalization. If hypoglycemic coma is diagnosed or suspected, the patient should be given a rapid intravenous injection of concentrated (50%) glucose solution. This should be followed by a continuous infusion of a more dilute (10%) glucose solution at a rate that will maintain the blood glucose at a level above 100 mg/dL. Patients should be closely monitored for a minimum of 24 to 48 hours, since hypoglycemia may recur after apparent clinical recovery.

**Metformin Hydrochloride**

Overdose of metformin hydrochloride has occurred, including ingestion of amounts >50 g. Hypoglycemia was reported in approximately 10% of cases, but no causal association with metformin hydrochloride has been established. Lactic acidosis has been reported in approximately 32% of metformin overdose cases (see **WARNINGS**). Metformin is dialyzable with a clearance of up to 170 mL/min under good hemodynamic conditions. Therefore, hemodialysis may be useful for removal of accumulated drug from patients in whom metformin overdosage is suspected.

**DOSAGE AND ADMINISTRATION**

**General Considerations**

**Dosage of GLUCOVANCE must be individualized on the basis of both effectiveness and tolerance while not exceeding the maximum recommended daily dose of 20 mg glyburide/2000 mg metformin.** GLUCOVANCE should be given with meals and should be initiated at a low dose, with gradual dose escalation as described below, in order to avoid hypoglycemia (largely due to glyburide), reduce GI side effects (largely due to metformin), and permit determination of the minimum effective dose for adequate control of blood glucose for the individual patient.

With initial treatment and during dose titration, appropriate blood glucose monitoring should be used to determine the therapeutic response to GLUCOVANCE and to identify the minimum effective dose for the patient. Thereafter, HbA$_1$c should be measured at intervals of approximately 3 months to assess the effectiveness of therapy. The therapeutic goal in all patients with type 2 diabetes is to decrease FPG, PPG, and HbA$_1$c to normal or as near normal as possible. Ideally, the response to therapy should be evaluated using HbA$_1$c (glycosylated hemoglobin), which is a better indicator of long-term glycemic control than FPG alone.
No studies have been performed specifically examining the safety and efficacy of switching to GLUCOVANCE therapy in patients taking concomitant glyburide (or other sulfonylurea) plus metformin. Changes in glycemic control may occur in such patients, with either hyperglycemia or hypoglycemia possible. Any change in therapy of type 2 diabetes should be undertaken with care and appropriate monitoring.

**In Patients with Inadequate Glycemic Control on Diet and Exercise**

*Recommended starting dose: 1.25 mg glyburide and 250 mg metformin hydrochloride once or twice daily with meals. GLUCOVANCE 1.25 mg/250 mg tablets are no longer available, however glyburide 1.25 mg and metformin hydrochloride 250mg tablets are available as individual components or a combination tablet.*

For patients with type 2 diabetes whose hyperglycemia cannot be satisfactorily managed with diet and exercise alone, the recommended starting dose is 1.25 mg glyburide and 250 mg metformin hydrochloride once a day with a meal. As initial therapy in patients with baseline HbA1c >9% or an FPG >200 mg/dL, a starting dose of 1.25 mg glyburide and 250 mg metformin hydrochloride twice daily with the morning and evening meals may be used. Dosage increases should be made in increments of 1.25 mg glyburide and 250 mg metformin hydrochloride per day every 2 weeks up to the minimum effective dose necessary to achieve adequate control of blood glucose. In clinical trials of GLUCOVANCE as initial therapy, there was no experience with total daily doses >10 mg/2000 mg per day. **GLUCOVANCE 5 mg/500 mg should not be used as initial therapy due to an increased risk of hypoglycemia.**

**GLUCOVANCE Use in Patients with Inadequate Glycemic Control on a Sulfonylurea and/or Metformin**

*Recommended starting dose: 2.5 mg/500 mg or 5 mg/500 mg twice daily with meals.*

For patients not adequately controlled on either glyburide (or another sulfonylurea) or metformin alone, the recommended starting dose of GLUCOVANCE is 2.5 mg/500 mg or 5 mg/500 mg twice daily with the morning and evening meals. In order to avoid hypoglycemia, the starting dose of GLUCOVANCE should not exceed the daily doses of glyburide or metformin already being taken. The daily dose should be titrated in increments of no more than 5 mg/500 mg up to the minimum effective dose to achieve adequate control of blood glucose or to a maximum dose of 20 mg/2000 mg per day.

For patients previously treated with combination therapy of glyburide (or another sulfonylurea) plus metformin, if switched to GLUCOVANCE, the starting dose should not exceed the daily
dose of glyburide (or equivalent dose of another sulfonylurea) and metformin already being taken. Patients should be monitored closely for signs and symptoms of hypoglycemia following such a switch and the dose of GLUCOVANCE should be titrated as described above to achieve adequate control of blood glucose.

**Addition of Thiazolidinediones to GLUCOVANCE Therapy**

For patients not adequately controlled on GLUCOVANCE, a thiazolidinedione can be added to GLUCOVANCE therapy. When a thiazolidinedione is added to GLUCOVANCE therapy, the current dose of GLUCOVANCE can be continued and the thiazolidinedione initiated at its recommended starting dose. For patients needing additional glycemic control, the dose of the thiazolidinedione can be increased based on its recommended titration schedule. The increased glycemic control attainable with GLUCOVANCE plus a thiazolidinedione may increase the potential for hypoglycemia at any time of day. In patients who develop hypoglycemia when receiving GLUCOVANCE and a thiazolidinedione, consideration should be given to reducing the dose of the glyburide component of GLUCOVANCE. As clinically warranted, adjustment of the dosages of the other components of the antidiabetic regimen should also be considered.

**Patients Receiving Colesevelam**

When colesevelam is coadministered with glyburide, maximum plasma concentration and total exposure to glyburide is reduced. Therefore, GLUCOVANCE should be administered at least 4 hours prior to colesevelam.

**Recommendations for Use in Renal Impairment**

Assess renal function prior to initiation of GLUCOVANCE and periodically thereafter.

GLUCOVANCE is contraindicated in patients with an estimated glomerular filtration rate (eGFR) below 30 mL/minute/1.73 m².

Initiation of GLUCOVANCE in patients with an eGFR between 30 – 45 mL/minute/1.73 m² is not recommended.

In patients taking GLUCOVANCE whose eGFR later falls below 45 mL/min/1.73 m², assess the benefit risk of continuing therapy.

Discontinue GLUCOVANCE if the patient’s eGFR later falls below 30 mL/minute/1.73 m². (See WARNINGS and PRECAUTIONS.).
Discontinuation for Iodinated Contrast Imaging Procedures

Discontinue GLUCOVANCE at the time of, or prior to, an iodinated contrast imaging procedure in patients with an eGFR between 30 and 60 mL/min/1.73 m²; in patients with a history of liver disease, alcoholism or heart failure; or in patients who will be administered intra-arterial iodinated contrast. Re-evaluate eGFR 48 hours after the imaging procedure; restart GLUCOVANCE if renal function is stable.

Specific Patient Populations

GLUCOVANCE is not recommended for use during pregnancy. The initial and maintenance dosing of GLUCOVANCE should be conservative in patients with advanced age, due to the potential for decreased renal function in this population. Any dosage adjustment requires a careful assessment of renal function.

HOW SUPPLIED

GLUCOVANCE® (Glyburide and Metformin HCl) Tablets

GLUCOVANCE 2.5 mg/500 mg tablet is a pale orange, capsule-shaped, bevel-edged, biconvex, film-coated tablet with "BMS" debossed on one side and "6073" debossed on the opposite side.

GLUCOVANCE 5 mg/500 mg tablet is a yellow, capsule-shaped, bevel-edged, biconvex, film-coated tablet with "BMS" debossed on one side and "6074" debossed on the opposite side.

<table>
<thead>
<tr>
<th>GLUCOVANCE</th>
<th>NDC 0087-xxxx-xx for unit of use</th>
</tr>
</thead>
<tbody>
<tr>
<td>Glyburide (mg) Metformin hydrochloride (mg) Bottle of 100</td>
<td></td>
</tr>
<tr>
<td>2.5 500</td>
<td>6073-11</td>
</tr>
<tr>
<td>5   500</td>
<td>6074-11</td>
</tr>
</tbody>
</table>

STORAGE

Store at temperatures up to 25°C (77°F). [See USP Controlled Room Temperature.]

Dispense in light-resistant containers.

GLUCOVANCE® is a registered trademark of Merck Santé S.A.S., an associate of Merck KGaA of Darmstadt, Germany. Licensed to Bristol-Myers Squibb Company.

GLUCOPHAGE® is a registered trademark of Merck Santé S.A.S., an associate of Merck KGaA of Darmstadt, Germany. Licensed to Bristol-Myers Squibb Company.
MICRONASE® is a registered trademark of Pharmacia & Upjohn Company LLC.

Distributed by:
Bristol-Myers Squibb Company
Princeton, NJ 08543 USA

[print code]
Rev April 2017
PATIENT INFORMATION ABOUT
GLUCOVANCE® (Glyburide and Metformin HCl) Tablets

WARNING: A small number of people who have taken metformin hydrochloride have developed a serious condition called lactic acidosis. Properly functioning kidneys are needed to help prevent lactic acidosis. Most people with kidney problems should not take GLUCOVANCE. (See Question Nos. 9-13.)

Q1. Why do I need to take GLUCOVANCE?

Your doctor has prescribed GLUCOVANCE to treat your type 2 diabetes. This is also known as non-insulin-dependent diabetes mellitus.

Q2. What is type 2 diabetes?

People with diabetes are not able to make enough insulin and/or respond normally to the insulin their body does make. When this happens, sugar (glucose) builds up in the blood. This can lead to serious medical problems, including kidney damage, amputations, and blindness. Diabetes is also closely linked to heart disease. The main goal of treating diabetes is to lower your blood sugar to a normal level.

Q3. Why is it important to control type 2 diabetes?

The main goal of treating diabetes is to lower your blood sugar to a normal level. Studies have shown that good control of blood sugar may prevent or delay complications, such as heart disease, kidney disease, or blindness.

Q4. How is type 2 diabetes usually controlled?

High blood sugar can be lowered by diet and exercise, a number of oral medications, and insulin injections. Before taking GLUCOVANCE you should first try to control your diabetes by exercise and weight loss. Even if you are taking GLUCOVANCE, you should still exercise and follow the diet recommended for your diabetes.

Q5. Does GLUCOVANCE work differently from other glucose-control medications?

Yes, it does. GLUCOVANCE combines 2 glucose-lowering drugs, glyburide and metformin. These 2 drugs work together to improve the different metabolic defects found in type 2 diabetes. Glyburide lowers blood sugar primarily by causing more of the body's own insulin to be released, and metformin lowers blood sugar, in part, by helping your body use your own insulin more effectively. Together, they are efficient in helping you to achieve better glucose control.
Q6. What happens if my blood sugar is still too high?

When blood sugar cannot be lowered enough by GLUCOVANCE your doctor may prescribe injectable insulin or take other measures to control your diabetes.

Q7. Can GLUCOVANCE cause side effects?

GLUCOVANCE, like all blood sugar-lowering medications, can cause side effects in some patients. Most of these side effects are minor. However, there are also serious, but rare, side effects related to GLUCOVANCE (see Q9-Q13).

Q8. What are the most common side effects of GLUCOVANCE?

The most common side effects of GLUCOVANCE are normally minor ones such as diarrhea, nausea, and upset stomach. If these side effects occur, they usually occur during the first few weeks of therapy. Taking your GLUCOVANCE with meals can help reduce these side effects.

Less frequently, symptoms of hypoglycemia (low blood sugar), such as lightheadedness, dizziness, shakiness, or hunger may occur. The risk of hypoglycemic symptoms increases when meals are skipped, too much alcohol is consumed, or heavy exercise occurs without enough food. Following the advice of your doctor can help you to avoid these symptoms.

Q9. Are there any serious side effects that GLUCOVANCE can cause?

People who have a condition known as glucose-6-phosphate dehydrogenase (G6PD) deficiency and who take GLUCOVANCE may develop hemolytic anemia (fast breakdown of red blood cells). G6PD deficiency usually runs in families. Tell your doctor if you or any members of your family have been diagnosed with G6PD deficiency before you start taking GLUCOVANCE.

GLUCOVANCE rarely causes serious side effects. The most serious side effect that GLUCOVANCE can cause is called lactic acidosis.

Q10. What is lactic acidosis and can it happen to me?

Metformin, one of the medicines in GLUCOVANCE can cause a rare but serious condition called lactic acidosis (a buildup of an acid in the blood) that can cause death. Lactic acidosis is a medical emergency and must be treated in the hospital.

Q11. Are there other risk factors for lactic acidosis?

Most people who have had lactic acidosis with metformin have other things that, combined with the metformin, led to the lactic acidosis. Tell your doctor if you have any of the following, because you have a higher chance for getting lactic acidosis with GLUCOVANCE if you:

- have severe kidney problems, or your kidneys are affected by certain x-ray tests that use injectable dye
- have liver problems
• drink alcohol very often, or drink a lot of alcohol in short-term “binge” drinking
• get dehydrated (lose a large amount of body fluids). This can happen if you are sick with a fever, vomiting, or diarrhea. Dehydration can also happen when you sweat a lot with activity or exercise and do not drink enough fluids
• have surgery
• have a heart attack, severe infection, or stroke

The best way to keep from having a problem with lactic acidosis from metformin is to tell your doctor if you have any of the problems in the list above. Your doctor may decide to stop your GLUCOVANCE for a while if you have any of these things.

Q12. What are the symptoms of lactic acidosis?

Call your doctor right away if you have any of the following symptoms, which could be signs of lactic acidosis:

• you feel cold in your hands or feet
• you feel dizzy or lightheaded
• you have a slow or irregular heartbeat
• you feel very weak or tired
• you have unusual (not normal) muscle pain
• you have trouble breathing
• you feel sleepy or drowsy
• you have stomach pains, nausea or vomiting

Q13. What does my doctor need to know to decrease my risk of lactic acidosis?

Before you take GLUCOVANCE, tell your doctor if you:

• have severe kidney problems
• have liver problems
• have heart problems, including congestive heart failure
• drink alcohol very often, or drink a lot of alcohol in short-term “binge” drinking
• are going to get an injection of dye or contrast agents for an x-ray procedure. GLUCOVANCE may need to be stopped for a short time. Talk to your doctor about when you should stop GLUCOVANCE and when you should start GLUCOVANCE again. See "What is the most important information I should know about GLUCOVANCE?"
• have any other medical conditions

Q14. Can I take GLUCOVANCE with other medications?
Remind your doctor that you are taking GLUCOVANCE when any new drug is prescribed or a change is made in how you take a drug already prescribed. GLUCOVANCE may interfere with the way some drugs work and some drugs may interfere with the action of GLUCOVANCE.

Do not take GLUCOVANCE if you are taking bosentan used for pulmonary arterial hypertension (PAH), which is high blood pressure in the vessels of the lungs.

Q15. What if I become pregnant while taking GLUCOVANCE?

Tell your doctor if you plan to become pregnant or have become pregnant. As with other oral glucose-control medications, you should not take GLUCOVANCE during pregnancy.

Usually your doctor will prescribe insulin while you are pregnant. As with all medications, you and your doctor should discuss the use of GLUCOVANCE if you are nursing a child.

Q16. How do I take GLUCOVANCE?

Your doctor will tell you how many GLUCOVANCE tablets to take and how often. This should also be printed on the label of your prescription. You will probably be started on a low dose of GLUCOVANCE and your dosage will be increased gradually until your blood sugar is controlled.

Q17. Where can I get more information about GLUCOVANCE?

This leaflet is a summary of the most important information about GLUCOVANCE. If you have any questions or problems, you should talk to your doctor or other healthcare provider about type 2 diabetes as well as GLUCOVANCE and its side effects. There is also a leaflet (package insert) written for health professionals that your pharmacist can let you read.

GLUCOVANCE® is a registered trademark of Merck Santé S.A.S., an associate of Merck KGaA of Darmstadt, Germany. Licensed to Bristol-Myers Squibb Company.

Other brands listed are the trademarks of their respective owners.

Distributed by:
Bristol-Myers Squibb Company
Princeton, NJ 08543 USA

[print code]
Rev April 2017